Teva is seeking to expand Treanda as a first line treatment for non-Hodgkin lymphoma.
The US Food and Drug Administration (FDA) is asking more data from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) about its first line treatment for non-Hodgkin lymphoma, Treanda, which is administered in combination with rituximab.
Teva acquired Treanda through its acquisition of Cephalon in 2011, and the drug generated $287 million in sales in the first half of 2011. Teva is seeking to expand the indication of Treanda to first line treatment for non-Hodgkin lymphoma.
Published by Globes [online], Israel business news - www.globes-online.com - on October 23, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012